Sutro Biopharma (STRO) Competitors $1.98 -0.11 (-5.26%) (As of 12:58 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STRO vs. OCS, CGEM, TECX, TRDA, ABUS, STOK, ALT, CRGX, EXAI, and ORICShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Oculis (OCS), Cullinan Therapeutics (CGEM), Tectonic Therapeutic (TECX), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), Stoke Therapeutics (STOK), Altimmune (ALT), CARGO Therapeutics (CRGX), Exscientia (EXAI), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Oculis Cullinan Therapeutics Tectonic Therapeutic Entrada Therapeutics Arbutus Biopharma Stoke Therapeutics Altimmune CARGO Therapeutics Exscientia ORIC Pharmaceuticals Oculis (NASDAQ:OCS) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has higher valuation and earnings, OCS or STRO? Oculis has higher earnings, but lower revenue than Sutro Biopharma. Oculis is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K715.43-$98.92M-$1.93-8.97Sutro Biopharma$160.96M1.04-$106.79M-$1.61-1.26 Does the MarketBeat Community favor OCS or STRO? Sutro Biopharma received 106 more outperform votes than Oculis when rated by MarketBeat users. However, 89.66% of users gave Oculis an outperform vote while only 66.00% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes2689.66% Underperform Votes310.34%Sutro BiopharmaOutperform Votes13266.00% Underperform Votes6834.00% Do analysts recommend OCS or STRO? Oculis currently has a consensus target price of $29.20, indicating a potential upside of 68.69%. Sutro Biopharma has a consensus target price of $11.13, indicating a potential upside of 448.03%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Sutro Biopharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Do insiders and institutionals have more ownership in OCS or STRO? 22.3% of Oculis shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer OCS or STRO? In the previous week, Sutro Biopharma had 5 more articles in the media than Oculis. MarketBeat recorded 7 mentions for Sutro Biopharma and 2 mentions for Oculis. Oculis' average media sentiment score of 0.47 beat Sutro Biopharma's score of 0.03 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is OCS or STRO more profitable? Sutro Biopharma has a net margin of -77.01% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% Sutro Biopharma -77.01%-101.89%-28.69% Which has more volatility and risk, OCS or STRO? Oculis has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. SummarySutro Biopharma beats Oculis on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.39M$2.98B$5.15B$9.28BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-1.2647.02135.4217.51Price / Sales1.04420.451,184.62142.21Price / CashN/A182.1340.4237.95Price / Book0.833.944.894.94Net Income-$106.79M-$42.03M$118.71M$225.59M7 Day Performance-17.14%-2.29%15.74%-1.07%1 Month Performance-26.18%9.14%15.70%7.23%1 Year Performance-47.27%21.39%34.85%22.97% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.675 of 5 stars$1.98-5.3%$11.13+461.9%-47.5%$163.27M$160.96M-1.30240OCSOculis2.2093 of 5 stars$17.07-0.1%$29.20+71.1%+74.5%$691.40M$980,000.00-8.852CGEMCullinan Therapeutics1.8035 of 5 stars$11.85+0.9%$31.67+167.2%+39.4%$690.00M$18.94M-4.1430Short Interest ↑TECXTectonic Therapeutic3.1868 of 5 stars$46.27+2.1%$72.25+56.1%N/A$682.62MN/A-7.70120Positive NewsTRDAEntrada Therapeutics3.1482 of 5 stars$18.24+3.3%$25.67+40.7%+32.4%$682.54M$129.01M11.11110News CoverageABUSArbutus Biopharma2.5031 of 5 stars$3.56+2.3%$5.50+54.5%+54.5%$674.58M$18.14M-8.0973Positive NewsSTOKStoke Therapeutics4.2129 of 5 stars$12.36+2.5%$20.83+68.6%+136.3%$654.71M$8.78M-5.74100ALTAltimmune1.9264 of 5 stars$9.12+1.0%$20.00+119.3%+9.5%$648.66M$52,000.00-5.8350Positive NewsCRGXCARGO Therapeutics1.8632 of 5 stars$13.94+1.5%$31.80+128.1%-18.7%$641.63MN/A-3.23116EXAIExscientia1.2963 of 5 stars$4.84+3.2%$7.00+44.6%-17.5%$632.93M$25.60M-3.21280High Trading VolumeORICORIC Pharmaceuticals3.7803 of 5 stars$8.45-0.8%$18.29+116.4%-11.4%$596.32MN/A-4.6880Insider TradeNews CoveragePositive NewsGap Down Related Companies and Tools Related Companies Oculis Alternatives Cullinan Therapeutics Alternatives Tectonic Therapeutic Alternatives Entrada Therapeutics Alternatives Arbutus Biopharma Alternatives Stoke Therapeutics Alternatives Altimmune Alternatives CARGO Therapeutics Alternatives Exscientia Alternatives ORIC Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STRO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STRO Stock Alerts